TY - JOUR
T1 - The Chicago Consensus on Peritoneal Surface Malignancies
T2 - Management of Appendiceal Neoplasms
AU - Chicago Consensus Working Group
AU - Schuitevoerder, Darryl
AU - Plana, Alejandro
AU - Izquierdo, Francisco J.
AU - Votanopoulos, Konstantinos I.
AU - Cusack, James C.
AU - Bijelic, Lana
AU - Cho, Clifford S.
AU - Gangi, Alexandra
AU - Gilbert, Erin W.
AU - Goodman, Martin D.
AU - Govindarajan, Anand
AU - Gushchin, Vadim
AU - Ihemelandu, Chukwuemeka
AU - Kelly, Kaitlyn J.
AU - Merkow, Ryan P.
AU - Pappas, Sam G.
AU - Abbott, Daniel E.
AU - Ahrendt, Steven A.
AU - Al-kasspooles, Mazin
AU - Alpert, Lindsay
AU - Amersi, Farin
AU - Arrington, Amanda K.
AU - Badgwell, Brian
AU - Barone, Robert M.
AU - Baumgartner, Joel M.
AU - Blazer, Dan G.
AU - Berri, Richard N.
AU - Brown, Charles Komen
AU - Catenacci, Daniel V.
AU - Chan, Carlos H.F.
AU - Choudry, M. Haroon A.
AU - Clarke, Callisia N.
AU - Cloyd, Jordan M.
AU - Dachman, Abraham H.
AU - Deneve, Jeremiah L.
AU - Dineen, Sean P.
AU - Fernandez, Leopoldo J.
AU - Eng, Oliver S.
AU - Fleshman, James W.
AU - Clark Gamblin, T.
AU - Georgakis, Georgios V.
AU - Grotz, Travis E.
AU - Hanna, Nader
AU - Harmath, Carla
AU - Hart, John
AU - Hayes-Jordan, Andrea
AU - Husain, Aliya N.
AU - Idrees, Kamran
AU - In, Haejin
AU - Polanco, Patricio M.
N1 - Funding Information:
James C. Cusack reports grants from Lumicell Inc. outside the submitted work. Carla Harmath serves on the medical advisory council of Accumen. Hedy Kindler reports personal fees and non-financial support from Inventiva, AstraZeneca, Boehringer Ingelheim, Merck, and Paredox; personal fees from Aldeyra Therapeutics, Bayer, BMS, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, and MedImmune; and funds to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, BMS, Deciphera, GSK, Lilly, Merck, MedImmune, Polaris, Verastem, and Blueprint, all outside the submitted work. Chih-Yi Liao reports personal fees from Eisai, Exelixis, and Klus Pharma outside the submitted work. Garrett M. Nash reports non-financial support from Intuitive outside the submitted work. Aytekin Oto reports grants from Philips Healthcare, Guerbet, and Profound Healthcare, and serves as a medical advisory board member for Profound Healthcare, all outside the submitted work. David P. Ryan reports personal fees from and equity in MPM Capital, equity in Acworth Pharmaceuticals, personal fees from Oncorus, Gritstone Oncology, Maverick Therapeutics, TCR Therapeutics, UpToDate, McGraw-Hill, and Johns Hopkins University Press, all outside the submitted work. Nita Ahuja reports grant funding from Cepheid and Astex, has served as a consultant to Ethicon, and has licensed methylation biomarkers to Cepheid. Jesus Esquivel reports personal fees from Eight Medical. The remaining authors disclosed no conflicts of interest. 2
Publisher Copyright:
© 2020, American Cancer Society and Society of Surgical Oncology.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
AB - The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
UR - http://www.scopus.com/inward/record.url?scp=85083306571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083306571&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-08316-w
DO - 10.1245/s10434-020-08316-w
M3 - Article
C2 - 32285275
AN - SCOPUS:85083306571
SN - 1068-9265
VL - 27
SP - 1753
EP - 1760
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 6
ER -